Drug Profile
Next-generation inhaled insulin - Nektar Therapeutics
Alternative Names: NGI; NKTR-034Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Nektar Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 09 Apr 2008 Discontinued - Phase-I for Diabetes mellitus in USA (Inhalation)
- 14 Nov 2007 Phase-I clinical trials in Diabetes mellitus in USA (Inhalation)
- 14 Nov 2007 Nektar Therapeutics and Pfizer reached an agreement on outstanding contractual issues on Next Generation Inhaled insulin product